PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
Phase 3
Completed
- Conditions
- Growth Hormone DeficiencyGrowth Retardation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00174278
- Locations
- ๐ซ๐ท
Pfizer Investigational Site, Paris, France
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Phase 2
Completed
- Conditions
- Attention Deficit Disorder With Hyperactivity
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT00174226
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Woodstock, Vermont, United States
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
Phase 3
Completed
- Conditions
- Fetal Growth Retardation
- Interventions
- Drug: Genotonorm (Somatropin)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT00174252
- Locations
- ๐ซ๐ท
Pfizer Investigational Site, Vandoeuvre Les Nancy, France
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
Phase 3
Completed
- Conditions
- Growth Disorder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00174421
Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age
Phase 3
Completed
- Conditions
- Growth Disorders
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00174408
Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
Phase 4
Completed
- Conditions
- Osteoarthritis, Hip
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00174317
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Wigan, United Kingdom
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small Cell Lung
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT00174356
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Hamilton, Ontario, Canada
A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
Phase 1
Completed
- Conditions
- Patients With Pace Makers But no Evidence of Ischemic Heart Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00174512
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Manchester, United Kingdom
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
Not Applicable
Completed
- Conditions
- Psychotic DisordersSchizophrenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00174200
- Locations
- ๐ท๐บ
Pfizer Investigational Site, Moscow, Russian Federation
Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age
Phase 2
Completed
- Conditions
- Infant, Very Low Birth WeightGrowth Hormone Therapy
- Interventions
- Other: Control Arm
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT00174460
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Tuebingen, Germany
ยฉ Copyright 2025. All Rights Reserved by MedPath